F2G Receives US FDA Orphan Drug Designation for Olorofim

Currently in Phase 2b development for the treatment of life-threatening fungal infections

MANCHESTER, UK / VIENNA, Austria – 09 March 2020 – F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead first-in-class candidate, olorofim (formerly F901318) for “treatment of invasive aspergillosis” and for “treatment of lomentospora/scedosporium infections”[1], which are invasive mould infections, for which there is significant unmet medical need. This development follows F2G’s announcement in November 2019 of olorofim as the first antifungal agent to be granted Breakthrough Therapy designation by the FDA.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH